<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01678248</url>
  </required_header>
  <id_info>
    <org_study_id>0048-12-ZIV</org_study_id>
    <nct_id>NCT01678248</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Intravitreal Avastin Injection for CRVO</brief_title>
  <official_title>The Effectiveness of Intravitreal Avastin Injection for CRVO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to determine the effectivness of intravitreal avastin injection on visual acuity on people
      that suffer from central retinal vein occlusion
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Central Retinal Vein Occlusion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients who suffer from CRVO and were injected by bevazicumab intravitrealy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients above 18 years old

          -  suffer from CRVO

          -  maximal visual acuity 6/15

        Exclusion Criteria:

          -  VA of LP

          -  retinal disease other than CRVO

          -  incomplete medical record

          -  follow up less than 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joseph pikkel, M.D</last_name>
    <phone>972508434206</phone>
    <email>pikel.y@ziv.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Otzem Chassid, M.D</last_name>
    <phone>972506266059</phone>
    <email>otzem.c@ziv.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otzem Chassid, M.D</last_name>
      <email>otzem.c@ziv.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Joseph Pikkel, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 29, 2012</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
